Do endocannabinoids acting via hepatic CB-1 contribute to NAFLD and hepatic insulin resistance?

J Clin Invest. 2022 Jan 4;132(1):e155330. doi: 10.1172/JCI155330.

Authors

George Kunos¹, Tony Jourdan², Joseph Tam³

Affiliations

¹ Laboratory of Physiologic Studies, National Institute on Alcohol Abuse and Alcoholism (NIAAA), NIH, Bethesda, Maryland, USA.
² Team Pathophysiology of Dyslipidemia, INSERM UMR1231 "Lipids, Nutrition, Cancer" and Université de Bourgogne Franche-Comté, Dijon, France.
³ Obesity and Metabolism Laboratory, Institute for Drug Research, School of Pharmacy, Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel.

No abstract available

Keywords: G protein–coupled receptors; Insulin signaling; Metabolism; Mouse models.

Publication types

Letter
Comment

MeSH terms

Endocannabinoids
Humans
Insulin Resistance*
Liver
Non-alcoholic Fatty Liver Disease* / genetics

Substances

Endocannabinoids